semaglutide cardiovascular outcomes align more closely with attained dose than achieved weight loss select study semaglutide The Trial

What began as a breakthrough in type 2 diabetes management has become one of the defining pharmaceutical stories of the decade

Patients should work closely with their healthcare providers and pharmacists to understand their options when generics become available

& Nadalin, W

It ensures your GLP-1 therapy delivers maximum benefit with minimal side effects

By increasing and prolonging active incretin levels, sitagliptin increases insulin release and decreases glucagon levels in the circulation in a glucose-dependent manner

This dual mechanism makes it highly effective for people with prediabetes or type 2 diabetes who struggle with glucose stability throughout the day